Oura Expanded Features as Company Delayed IPO
The wearable technology firm has launched new health tracking tools in 30 markets while pausing its public listing.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you trust wearable devices to accurately track your body's response to medication?
Oura has expanded its GLP-1 Insights and Health Radar features to over 30 international markets, including the European Union, Canada, and Saudi Arabia. Simultaneously, the company has officially postponed its planned Nasdaq initial public offering.
Why it matters
Oura cited ongoing uncertainty within the IPO market as the primary reason for shelving its public listing plans. The feature expansion aims to capture growing demand from users managing weight-loss medications across various digital platforms.
Oura generated $1.21 billion in revenue during the first nine months of 2026, representing a 74 percent growth rate. The company currently maintains a base of 5.7 million paying members.
The players
Oura
This Finland-based company specializes in the development of wearable health technology, including smart rings that monitor sleep and activity patterns.
Anthropic
This artificial intelligence startup is an industry competitor in the technology sector and is currently planning its own public market debut.
The details
The newly available features include GLP-1 Insights, which tracks medication side effects, and Health Radar, which utilizes Blood Pressure Signals to monitor heart strain. These tools are compatible with the Oura Ring Gen3 and later hardware models.
Timeline
October 6, 2026: Oura announced the feature expansion and the delay of its IPO.
Q1-Q3 2026: The company recorded a 74 percent increase in revenue.
November 15, 2026: Anthropic is currently scheduled to go public.
2030: Industry analysts project 100 million people will use GLP-1 drugs worldwide.
Market Landscape
Oura's strategic pivot reflects a broader trend of high-growth technology companies exercising caution in the current capital markets environment. This shift mirrors the approach of other major players who are recalibrating their public listing timelines to ensure more favorable valuations.
Customers in the newly supported markets can now access advanced health monitoring tools directly through their existing Oura Ring hardware. There are currently no announced changes to subscription pricing for current or prospective members.
The takeaway
The integration of GLP-1 tracking into wearable devices marks a significant step toward unifying medication management with biometric monitoring. Users should view these automated features as supplemental data for health discussions with their medical providers.
What happens next
Anthropic is currently scheduled to initiate its public offering on November 15, 2026.
Further reading
For more information on the evolving medical technology sector, visit the /business/industry/healthcare/ section.
Live Poll
Do you trust wearable devices to accurately track your body's response to medication?
